Bagir Group (BAGR LN) Interim results | M&C Saatchi (SAA LN) H1 outperformance provides a huge buffer against uncertainty | Summit Therapeutics (SUMM LN) H1’s highlight antibiotics programmes on track

21 Sep 2018
Morning Song

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Morning Song
- Published:
21 Sep 2018 -
Author:
Singer CM Team -
Pages:
9 -
Bagir Group (BAGR LN) Interim results | M&C Saatchi (SAA LN) H1 outperformance provides a huge buffer against uncertainty | Summit Therapeutics (SUMM LN) H1’s highlight antibiotics programmes on track